STOCK TITAN

Lynx1 Capital’s 16.8% passive stake in GH Research (GHRS) revealed in 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

GH Research PLC received an updated ownership disclosure showing that investment manager Lynx1 Capital Management LP and Weston Nichols together beneficially own 10,406,575 ordinary shares. This represents 16.8% of GH Research’s ordinary shares, based on 62,029,395 shares outstanding as of September 30, 2025.

The shares are held through the Lynx1 Master Fund LP and a managed account, with Lynx1 and Nichols sharing voting and dispositive power over the stake. They certify that the position was not acquired to change or influence control of GH Research, indicating a passive investment intent under Schedule 13G rules.

Positive

  • None.

Negative

  • None.

Insights

Lynx1 and Weston Nichols disclose a sizable but passive 16.8% stake in GH Research.

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 10,406,575 GH Research ordinary shares, equal to 16.8% of the class based on 62,029,395 shares outstanding as of September 30, 2025. Voting and dispositive power are shared, concentrated in a single institutional complex.

The filing uses Schedule 13G, and the certification states the shares were not acquired or held to change or influence control. That signals a passive holder status rather than an activist approach. Actual implications for governance depend on how this stake is exercised in future votes, though no specific actions or plans are indicated in this disclosure.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Lynx1 Capital Management LP
Signature:/s/ Weston Nichols
Name/Title:By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
Date:02/17/2026
Weston Nichols
Signature:/s/ Weston Nichols
Name/Title:Weston Nichols, Individually
Date:02/17/2026

FAQ

What stake does Lynx1 Capital Management hold in GH Research (GHRS)?

Lynx1 Capital Management LP and Weston Nichols report owning 10,406,575 GH Research ordinary shares, representing 16.8% of the class. This gives them a significant minority position, with shared voting and dispositive power over the reported stake.

Is the Lynx1 position in GH Research (GHRS) an activist or passive stake?

The investors certify the GH Research shares were not acquired to change or influence control. Filing on Schedule 13G and this certification together indicate a passive investment intent rather than an activist or control-seeking position at this time.

How was the 16.8% ownership in GH Research (GHRS) calculated?

The 16.8% figure is based on 10,406,575 ordinary shares beneficially owned versus 62,029,395 GH Research ordinary shares outstanding as of September 30, 2025, as reported in the company’s Form 6-K Exhibit 99.1 filed on November 6, 2025.

Who actually holds the GH Research (GHRS) shares reported by Lynx1?

The ordinary shares are directly held by Lynx1 Master Fund LP and a managed account. Lynx1 Capital Management LP, as investment manager, and Weston Nichols, through control of the general partner, share voting and dispositive power over these holdings.

Does Lynx1’s 16.8% GH Research (GHRS) stake give it control of the company?

A 16.8% stake is significant but does not constitute majority control. The filing also states the securities were not acquired to change or influence control, indicating the position is a sizable but non-controlling, passive ownership interest in GH Research.

What type of security in GH Research (GHRS) is owned by Lynx1?

Lynx1 and Weston Nichols beneficially own GH Research’s ordinary shares with a nominal value of $0.025 per share. These ordinary shares are the company’s primary equity class referenced in the Schedule 13G/A ownership disclosure.
Gh Research Plc

NASDAQ:GHRS

GHRS Rankings

GHRS Latest News

GHRS Latest SEC Filings

GHRS Stock Data

949.05M
45.42M
Biotechnology
Healthcare
Link
Ireland
Dublin